Certain antibiotics, particularly piperacillin, have been reported to be associated with a high incidence of allergic reactions in patients with cystic fibrosis. We initiated a study to determine the relative frequency of allergic reactions, ie, drug-induced fever and rash, to parenteral beta-lactam antibiotics in adult patients with cystic fibrosis. Charts of 111 patients were reviewed for each hospitalization to assess allergic reactions. Of 90 evaluable patients, 26 patients developed one or more allergic reactions to beta-lactam antibiotics. The number of allergic reactions per number of patients receiving specific antibiotics were carbenicillin (4/56), mezlocillin (7/42), piperacillin (11/31), ticarcillin (1/20), cefazolin (0/24), ceftazidime (1/35), imipenem/cilastatin (4/16) , and nafcillin (3/36 
METHODS
Medical records from adult patients with CF admitted to the study institution from 1980 to 1991 were reviewed. Once identified, all hospital admissions for each patient were retrospectively evaluated. Patients' conditions must have been diagnosed as CF by sweat chloride test and clinical history. Charts were reviewed to assess the development of allergic drug reactions, particularly dermatologic reactions and drug-induced fever. Cutaneous reactions were those known or presumed to be allergic in nature and included the occurrence of urticaria, generalized morbilliform exanthematous eruptions, or generalized pruritus, which resolved after discontinuation of the offending antibiotic and the skin rash was not attributed to another cause. Drug-induced fever was defined according to the criteria by Young et al. 7 Patients must have had the following: (1) temperature more than 380C oral or rectal equivalent; (2) no new infection or other cause of fever detected from results of physical examination, appropriate cultures, and other studies; (3) absence of underlying conditions that might cause a febrile state; (4) development of fever coincided temporally with the administration of the offending antibiotic; (5) fever disappeared within 72 h after the discontinuation of the antibiotic without other interventions; and (6) the patient remained afebrile for at least 72 h after the temperature returned to normal (370C).7
Patients were considered to not have DIF if they had fever beyond day 3 postantibiotic discontinuation, received blood products within 72 h before onset of suspected DIF, were started on agents, eg, phenytoin, known to have a high incidence of DIF within 4 All admissions for which the patient received at least one parenteral beta-lactam were reviewed. Patient demographics, laboratory data, temperatures during therapy, and documented adverse effects from drug therapy for each patient hospitalization were recorded. Statistically significant differences were determined by interval-based testing with 95 percent confidence intervals using a normal distribution.9 Differences in the proportions of allergic reactions among the individual antibiotics and drug groups were compared. Drugs were grouped as penicillins, cephalosporins, or thienamycin. The frequency of allergic reactions was also compared with acylaminopenicillins (piperacillin and mezlocillin) and carboxypenicillins (carbenicillin and ticarcillin).
RESULTS
Charts of 111 patients followed-up at the study institution were reviewed for each hospitalization. More than 90 percent of admissions were for pulmonary exacerbations. Other indications for admission were primarily gastrointestinal problems. Sixty percent of the patients were women. Twenty-one patients were excluded because 14 patients had received concurrent antipyretics or had received corticosteroids during each of their hospital admissions and 7 excluded due to no hospitalizations at the study institution. Of the 90 patients, 40 received at least 3 different parenteral beta-lactam antibiotics during different hospitalizations. Twenty-six (28.8 percent) of the 90 patients developed probable reactions to parenteral beta-lactams while at the study institution. The number of allergic reactions per number of patients that received the specific antibiotic were carbenicillin (4/56), ticarcillin (1/20), mezlocillin (7/42), piperacillin (11/31), nafcillin (3/36), imipenem/cilastatin (4/16), cefazolin (0/24), and ceftazidime (1/35). The mean times for onset and resolution of DIF and maximum temperature were 10.1 (±5.4) days, 1.7 (±0.9) days, and 38.70C, respectively. The mean onset and time for resolution of rash were 8.1 (±5.4) days and 2.4 (±1.3) days, respectively. Tables 1 to 3 summarize data on patients who developed allergic reactions. Of the 18 dermatologic reactions, 6 were maculopapular, 4 were urticarial, 4 were facial swelling, and 4 had pruritus without a rash.
When penicillins and cephalosporins were compared as groups, the frequency of allergic reactions was greater with the former group. Carboxypenicillins (carbenicillin and ticarcillin) had a lower incidence of allergic reactions than that of acylaminopenicillins. When examined individually, piperacillin and mezlocillin each had a statistically greater incidence of allergic reactions than ceftazidime or cefazolin. Due to a few courses of therapy, the following antibiotics were not included in the data analysis: ampicillin, aztreonam, cephalothin, cefamandole, cefsulodin, methicillin, and moxalactam. Of these drugs, one patient developed an allergic reaction to aztreonam.
In the patients with CF allergic to piperacillin and who had also received mezlocillin (n=7), three were also allergic to mezlocillin. All allergic reactions were reversible on discontinuation of the offending antibiotic. There was a high suspicion of a severe allergic reaction to piperacillin in one patient with CF who was mechanically ventilated shortly after the onset of fever on day 12 of antibiotic therapy. The reaction resolved quickly and mechanical ventilation was stopped several days after the piperacillin was discontinued. One patient developed fever and shortness of breath 4 days after initiation of piperacillin therapy, which resolved within 48 h after drug discontinuation. Another patient had an anaphylactic reaction to mezlocillin, which responded to epinephrine. Because of the lack of consistency in obtaining eosinophil counts on admission and throughout hospitalization, this information was not used. Although not included in data analysis, of the 26 patients with presumptive allergic reactions to beta-lactams, 7 had a history of sulfa allergy, whereas in the 64 patients with no reactions, only one had a history of sulfa allergy.
DISCUSSION
The development of allergic reactions to antibiotics in patients with CF has important implications. Not only is morbidity an issue with antibiotic-associated allergic reactions but also when a patient does have such a reaction, generally the antibiotic is avoided in that patient again, thus limiting an already narrow armamentarium of drugs for P aeruginosa. We examined the incidence of allergic reactions in an adult CF patient population and found that certain beta-lactam antibiotics were more likely to produce allergic reactions than others in the--same class. In particular, acylaminopenicillins (mezlocillin and piperacillin) and the thienamycin, imipenem/cilastatin, were associated with a higher incidence of allergic reactions than cephalosporins and certain other betalactams used in these patients.
Because rechallenge with an antibiotic in an "allergic" patient is typically avoided, documentation of allergic reactions in the patients with CF is often based on clinical observations and is, therefore, presumptive. Patients with CF uncommonly (<50 percent) have fever during acute exacerbations, and if they do, the temperature generally returns to normal within several days after admission. The fever associated with beta-lactams in CF patients begins 7 to 14 days after initiation of antibiotic therapy and generally resolves within 48 h after stopping the drug. In a general patient population, documentation of DIF is complicated by the presence of other disease conditions, superinfections, and concurrent medications. In contrast to the general non-CF patient population, the development of fever 7 to 14 days after initiation of antibiotic therapy in patients with CF is almost exclusively from DIF, thus allowing for retrospective assessment. However, the retrospective nature of this study does not provide a totally accurate determination of true incidence of allergic reactions. Only a randomized, prospective study provides such data. It should be noted that prior studies evaluating only single courses of antibiotics do receiving piperacillin.14'5 In a study by Agostini et al,5 the incidence of DIF was greater with piperacillin (18.7 percent) than azlocillin (3.6 percent), ceftazidime (0 percent), and cefoperazone (0 percent). The typical onset of DIF in these studies was 10 days with resolution occurring generally within 48 h after piperacillin discontinuation. The high incidence of DIF in the CF population has been thought to be the result of the frequent use of complex penicillins along with the presence of a hyperimmune state. The actual mechanism of this allergic reaction, however, has yet to be determined. The frequent courses, long duration, and high doses of antibiotic therapy in CF patients most assuredly contributes to the relatively high incidence of allergic reaction in these patients. These factors may be more important than the underlying disease itself.
Certain antibiotics are more likely than others to be associated with the development of drug allergies. Generally, penicillins are more likely to cause allergic reactions than are cephalosporins. As observed in this study, sulfa drugs are also a common cause of hypersensitivity, particularly in the patients with CF who ultimately had an allergic reaction to a betalactam. Imipenem/cilastatin has been reported to exhibit a high degree of immune cross-reactivity with penicillins.'0 In two studies of patients with CF the incidence of allergic reactions to imipenem/cilastatin was 2/19 (10.5 percent) patients1l and 1/10 (10 percent) patients.12 We observed a higher incidence, 25 percent, with imipenem/cilastatin. This may be related to some subjects receiving multiple courses of the drug and are, therefore, more likely to manifest an allergic reaction. We were unable to identify published studies of mezlocillin in patients with CF and, therefore, could not compare our results with others. In a study comparing two other acylaminopenicillins, azlocillin and piperacillin, the incidence of allergic reactions was 7/20 patients and 14/30 patients with CF, respectively.13 Thus, our observation of a high incidence of probable allergic reactions to mezlocillin is in keeping with studies of other acylaminopenicillins.
The frequency of penicillin allergy in the general population has been estimated to be between 1 and 10 percent.14 Most of these reactions are cutaneous in nature. Drug fever has been reported to be the sole primary adverse effect in 3 to 4 percent of all reported adverse drug reactions.7 Certain antibiotics appear to have a greater tendency to be associated with allergic reactions. Recently, Lang et al15 evaluated the incidence of allergic reactions in patients with osteomyelitis who received either carbenicillin, mezlocillin, or piperacillin for prolonged periods, generally 4 to 8 weeks. Drug-induced fever developed in 5.7, 40, and 33 percent of patients receiving carbenicillin, mezlocillin, and piperacillin, respectively. The onset of DIF ranged from 9 to 32 days after initiation of antibiotic therapy. The incidence of DIF secondary to mezlocillin in that study was much more than that reported in the literature. The DIF developed more frequently in patients receiving individual courses greater than 750 and 230 g of carbenicillin and mezlocillin, respectively. The authors proposed that the development of DIF may be from a cumulative dose or duration of therapy phenomenon. A study of 390 general hospital patients was undertaken to assess the incidence and presentation of DIF from antibiotics. 16 The incidence of DIF ranged from 8 to 17 percent with cephlosporins and 17 percent incidence with piperacillin. The high incidences due to certain antibiotics observed in non-CF patients suggest that patients with CF may not be unique relative to the frequency of allergic reactions.
Because drug-fever may precede the development of more serious manifestations eg, hepatitis and exfoliative dermatitis, its recognition may be important. Drug-induced fever is a delayed allergic reaction, and thus, immunologic testing, eg, skin tests, is not useful in predicting a subsequent reaction. Most allergic reactions observed in our patients were mild and reversible. One patient had anaphylaxis, and two others, one seriously, developed respiratory compromise. If patients who had mild reactions continued to receive the offending antibiotics, a greater number of potentially serious reactions may have occurred.
The present study confirms the high incidence of allergic reactions secondary to piperacillin in patients with CF seen in other investigations.1'2'4-6 Druginduced fever constituted nearly all the documented adverse reactions from piperacillin in the present study. Allergic reactions to mezlocillin and imipenem included rash and DIF, suggesting the possibility of tendencies of different manifestations of reactions to these agents. A prior clinical trial in patients with cancer comparing ticarcillin and mezlocillin revealed a 46 percent incidence of rash due to mezlocillin whereas allergic reactions did not occur with ticarcillin. 17 In summary, the results of our study confirm the findings of other investigators for piperacillin and introduce new observations for mezlocillin and imipenem/cilastatin in a group of adult patients with CF. We conclude that piperacillin, mezlocillin, and imipenem/cilastatin are associated with an increased incidence of allergic reactions in patients with CF. There are several implications of this study. First, this study emphasizes that clinicians need to be aware of the character of allergic reactions, rash, and DIF, which occur in patients with CF. Second, clinicians should be aware that certain antibiotics are more apt to cause allergic reactions than others in patients with CF. Finally, although allergic reactions were reversible in all patients, two patients in our series developed severe reactions that were life-threatening. Consideration should be given to the risk of allergic reactions from certain beta-lactam antibiotics when choosing and monitoring antibiotic therapy in patients with CF.
